A Biotechnology company that develops a new class of potent and off-the-shelf therapeutic cancer vaccines based on a proprietary cell line of Plasmacytoid Dendritic Cells
About
PDC*line Pharma is a clinical-stage biotech company that develops an innovative class of active cancer vaccines, based on a GMP-grade allogeneic therapeutic cell line of Plasmacytoid Dendritic Cells. PDC*line is much more potent than conventional dendritic cell-based vaccines in priming and boosting antitumor antigen-specific cytotoxic T-cells, including the T-cells specific for neoantigens, and is synergistic with checkpoint inhibitors. The technology can potentially be applied to any type of cancer. PDC*line Pharma focuses on the development of PDC*lung01, a candidate for Non-Small-Cell Lung Cancer (NSCLC) currently in phase I/II trials, and PDC*neo with neoantigens in preclinical development. The company has a staff of 42, with an experienced management team. It has raised more than €62M in equity and non-dilutive funding. PDC*line Pharma granted an exclusive license to the LG Chem in South Korea for the development and commercialization of the PDC*lung01 cancer vaccine.